Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases.
Ross Andrew SooTakashi SetoJhanelle E GrayEllen ThielAliki TaylorWilliam SawyerParisa KarimiElizabeth MarchlewiczMatthew BrouillettePublished in: Drugs - real world outcomes (2021)
In an analysis of US claims data, nearly half of patients discontinued 1L EGFR-TKIs, and 46% who initiated 2L received osimertinib. As nearly a quarter of patients who discontinued 1L EGFR-TKIs did not receive 2L treatment, this study highlights the need for optimal 1L treatment in EGFRm locally advanced/metastatic NSCLC.
Keyphrases
- epidermal growth factor receptor
- small cell lung cancer
- locally advanced
- squamous cell carcinoma
- advanced non small cell lung cancer
- tyrosine kinase
- end stage renal disease
- rectal cancer
- health insurance
- neoadjuvant chemotherapy
- chronic kidney disease
- peritoneal dialysis
- machine learning
- big data
- ejection fraction
- brain metastases
- patient reported
- phase ii study